These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 15059702)

  • 41. Comparing diurnal and nocturnal effects of brinzolamide and timolol on intraocular pressure in patients receiving latanoprost monotherapy.
    Liu JH; Medeiros FA; Slight JR; Weinreb RN
    Ophthalmology; 2009 Mar; 116(3):449-54. PubMed ID: 19157559
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Intraocular pressure response to medication in a clinical setting: the Marshfield Clinic Personalized Medicine Research Project.
    McCarty CA; Mukesh BN; Kitchner TE; Hubbard WC; Wilke RA; Burmester JK; Patchett RB
    J Glaucoma; 2008 Aug; 17(5):372-7. PubMed ID: 18703947
    [TBL] [Abstract][Full Text] [Related]  

  • 43. On the treatment effect in clinical trials with dropout.
    Shao J; Zhong B
    J Biopharm Stat; 2006; 16(1):25-33. PubMed ID: 16440835
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of unstratified and centre-stratified randomization in multi-centre clinical trials.
    Anisimov VV
    Pharm Stat; 2011; 10(1):50-9. PubMed ID: 20112277
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A novel metric to assess the clinical utility of a drug in the presence of efficacy and dropout information.
    Goyal N; Gomeni R
    Clin Pharmacol Ther; 2012 Feb; 91(2):215-9. PubMed ID: 22089266
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Intent-to-treat analysis for clinical trials: use of data collected after termination of treatment protocol.
    Mazumdar S; Houck PR; Liu KS; Mulsant BH; Pollock BG; Dew MA; Reynolds CF
    J Psychiatr Res; 2002; 36(3):153-64. PubMed ID: 11886693
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Baseline observation carry forward: reasoning, properties, and practical issues.
    Shao J; Jordan DC; Pritchett YL
    J Biopharm Stat; 2009 Jul; 19(4):672-84. PubMed ID: 20183433
    [TBL] [Abstract][Full Text] [Related]  

  • 48. On the practical application of mixed effects models for repeated measures to clinical trial data.
    Andersen SW; Millen BA
    Pharm Stat; 2013; 12(1):7-16. PubMed ID: 23239585
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The One-Eye drug trial revisited.
    Piltz-Seymour J; Jampel H
    Ophthalmology; 2004 Mar; 111(3):419-20. PubMed ID: 15019312
    [No Abstract]   [Full Text] [Related]  

  • 50. Clinical trials simulation: a statistical approach.
    Westfall PH; Tsai K; Ogenstad S; Tomoiaga A; Moseley S; Lu Y
    J Biopharm Stat; 2008; 18(4):611-30. PubMed ID: 18607794
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [V: p values: what they do tell and what they don't...].
    Krummenauer F
    Klin Monbl Augenheilkd; 2002 Dec; 219(12):896-8. PubMed ID: 12548477
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Performance of nonlinear mixed effects models in the presence of informative dropout.
    Björnsson MA; Friberg LE; Simonsson US
    AAPS J; 2015 Jan; 17(1):245-55. PubMed ID: 25421458
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Intent to treat].
    Glemain P
    Prog Urol; 2000 Dec; 10(6):1255-7. PubMed ID: 11217571
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Parallel, AA/BB, AB/BA and Balaam's design: efficient and maximin choices when testing the treatment effect in a mixed effects linear regression.
    Candel MJ
    Pharm Stat; 2012; 11(2):97-106. PubMed ID: 22337606
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A median-based test under informative dropout: the one-sample case.
    Liang WM; Brown MB
    Control Clin Trials; 1997 Oct; 18(5):445-59. PubMed ID: 9315427
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A joint model for nonlinear longitudinal data with informative dropout.
    Hu C; Sale ME
    J Pharmacokinet Pharmacodyn; 2003 Feb; 30(1):83-103. PubMed ID: 12800808
    [TBL] [Abstract][Full Text] [Related]  

  • 57. An evaluation of the trimmed mean approach in clinical trials with dropout.
    Wang MD; Liu J; Molenberghs G; Mallinckrodt C
    Pharm Stat; 2018 May; 17(3):278-289. PubMed ID: 29624854
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Thinking while balancing: what to do about replacing dropouts.
    Shader RI; Harmatz JS; Greenblatt DJ
    J Clin Psychopharmacol; 1994 Aug; 14(4):229. PubMed ID: 7962677
    [No Abstract]   [Full Text] [Related]  

  • 59. Adjusting for drop-out in clinical trials with repeated measures: design and analysis issues.
    Wu MC; Albert PS; Wu BU
    Stat Med; 2001 Jan; 20(1):93-108. PubMed ID: 11135350
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Estimating the distribution of nonterminal event time in the presence of mortality or informative dropout.
    Jiang H; Chappell R; Fine JP
    Control Clin Trials; 2003 Apr; 24(2):135-46. PubMed ID: 12689735
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.